539 related articles for article (PubMed ID: 21372035)
1. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.
Carroll RE; Benya RV; Turgeon DK; Vareed S; Neuman M; Rodriguez L; Kakarala M; Carpenter PM; McLaren C; Meyskens FL; Brenner DE
Cancer Prev Res (Phila); 2011 Mar; 4(3):354-64. PubMed ID: 21372035
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of colonic aberrant crypt foci by curcumin in rats is affected by age.
Kwon Y; Malik M; Magnuson BA
Nutr Cancer; 2004; 48(1):37-43. PubMed ID: 15203376
[TBL] [Abstract][Full Text] [Related]
3. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
[TBL] [Abstract][Full Text] [Related]
5. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.
Wali RK; Bianchi L; Kupfer S; De La Cruz M; Jovanovic B; Weber C; Goldberg MJ; Rodriguez LM; Bergan R; Rubin D; Tull MB; Richmond E; Parker B; Khan S; Roy HK
PLoS One; 2018; 13(4):e0193544. PubMed ID: 29617381
[TBL] [Abstract][Full Text] [Related]
6. Aberrant crypt foci: endoscopic assessment and cell kinetics characterization.
Figueiredo P; Donato M; Urbano M; Goulão H; Gouveia H; Sofia C; Leitão M; Freitas D
Int J Colorectal Dis; 2009 Apr; 24(4):441-50. PubMed ID: 18769883
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance.
Sharma RA; Euden SA; Platton SL; Cooke DN; Shafayat A; Hewitt HR; Marczylo TH; Morgan B; Hemingway D; Plummer SM; Pirmohamed M; Gescher AJ; Steward WP
Clin Cancer Res; 2004 Oct; 10(20):6847-54. PubMed ID: 15501961
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
9. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy.
Anderson JC; Swede H; Rustagi T; Protiva P; Pleau D; Brenner BM; Rajan TV; Heinen CD; Levine JB; Rosenberg DW
Cancer Causes Control; 2012 Feb; 23(2):355-61. PubMed ID: 22187142
[TBL] [Abstract][Full Text] [Related]
10. Effect of azoxymethane and curcumin on transcriptional levels of cyclooxygenase-1 and -2 during initiation of colon carcinogenesis.
Kwon Y; Magnuson BA
Scand J Gastroenterol; 2007 Jan; 42(1):72-80. PubMed ID: 17190766
[TBL] [Abstract][Full Text] [Related]
11. Beta-catenin expression is altered in dysplastic and nondysplastic aberrant crypt foci of human colon.
Mi B; Wang X; Bai Y; Gong W; Wang X; Geng Y; Wang J; Zhang H; Jiang B
Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):294-300. PubMed ID: 19247180
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model.
Tsuda M; Okamoto K; Muguruma N; Sannomiya K; Nakagawa T; Miyamoto H; Kitamura S; Goji T; Kimura T; Okahisa T; Izumi K; Takayama T
J Gastroenterol Hepatol; 2013 Oct; 28(10):1616-23. PubMed ID: 23730936
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
Shpitz B; Klein E; Buklan G; Neufeld D; Nissan A; Freund HR; Grankin M; Bernheim J
Gut; 2003 Nov; 52(11):1598-601. PubMed ID: 14570729
[TBL] [Abstract][Full Text] [Related]
15. A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps.
Briata IM; Paleari L; Rutigliani M; Petrera M; Caviglia S; Romagnoli P; Libera MD; Oppezzi M; Puntoni M; Siri G; Lazzeroni M; Howells L; Singh R; Brown K; DeCensi A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681684
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression.
Tessitore L; Davit A; Sarotto I; Caderni G
Carcinogenesis; 2000 Aug; 21(8):1619-22. PubMed ID: 10910967
[TBL] [Abstract][Full Text] [Related]
17. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon.
Rao CV; Simi B; Reddy BS
Carcinogenesis; 1993 Nov; 14(11):2219-25. PubMed ID: 8242846
[TBL] [Abstract][Full Text] [Related]
18. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
[TBL] [Abstract][Full Text] [Related]
19. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
Garcea G; Berry DP; Jones DJ; Singh R; Dennison AR; Farmer PB; Sharma RA; Steward WP; Gescher AJ
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):120-5. PubMed ID: 15668484
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Limburg PJ; Mahoney MR; Ziegler KL; Sontag SJ; Schoen RE; Benya R; Lawson MJ; Weinberg DS; Stoffel E; Chiorean M; Heigh R; Levine J; Della'Zanna G; Rodriguez L; Richmond E; Gostout C; Mandrekar SJ; Smyrk TC;
Cancer Prev Res (Phila); 2011 Feb; 4(2):259-69. PubMed ID: 21209397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
